Key facts
- Biomunex Pharmaceuticals’s last known valuation is $43.6M (Feb 2021).
- It has raised $6.4M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Bpifrance, Agoranov, Eurobail Formation, French Government, L'Agence Nationale de la Recherche — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Biomunex Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Biomunex Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biomunex Pharmaceuticals
Developer of immunotherapies designed to deliver therapeutics in the area of oncology. The company's immunotherapies offer to develop drug candidates with high anti-tumor potential, superior manufacturability, and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 13
- Website
- biomunex.com/
- Ownership
- Privately Held (backing)
Biomunex Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomunex Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomunex Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.